Literature DB >> 20307281

Current sample size conventions: flaws, harms, and alternatives.

Peter Bacchetti1.   

Abstract

BACKGROUND: The belief remains widespread that medical research studies must have statistical power of at least 80% in order to be scientifically sound, and peer reviewers often question whether power is high enough. DISCUSSION: This requirement and the methods for meeting it have severe flaws. Notably, the true nature of how sample size influences a study's projected scientific or practical value precludes any meaningful blanket designation of <80% power as "inadequate". In addition, standard calculations are inherently unreliable, and focusing only on power neglects a completed study's most important results: estimates and confidence intervals. Current conventions harm the research process in many ways: promoting misinterpretation of completed studies, eroding scientific integrity, giving reviewers arbitrary power, inhibiting innovation, perverting ethical standards, wasting effort, and wasting money. Medical research would benefit from alternative approaches, including established value of information methods, simple choices based on cost or feasibility that have recently been justified, sensitivity analyses that examine a meaningful array of possible findings, and following previous analogous studies. To promote more rational approaches, research training should cover the issues presented here, peer reviewers should be extremely careful before raising issues of "inadequate" sample size, and reports of completed studies should not discuss power.
SUMMARY: Common conventions and expectations concerning sample size are deeply flawed, cause serious harm to the research process, and should be replaced by more rational alternatives.

Entities:  

Mesh:

Year:  2010        PMID: 20307281      PMCID: PMC2856520          DOI: 10.1186/1741-7015-8-17

Source DB:  PubMed          Journal:  BMC Med        ISSN: 1741-7015            Impact factor:   8.775


  28 in total

Review 1.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

2.  Are large clinical trials in rapidly lethal diseases usually unethical?

Authors:  David F Horrobin
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

3.  Power is indeed irrelevant in interpreting completed studies.

Authors:  Stephen J Senn
Journal:  BMJ       Date:  2002-11-30

4.  Are statistical contributions to medicine undervalued?

Authors:  Norman E Breslow
Journal:  Biometrics       Date:  2003-03       Impact factor: 2.571

5.  Underpowering in randomized trials reporting a sample size calculation.

Authors:  Andrew J Vickers
Journal:  J Clin Epidemiol       Date:  2003-08       Impact factor: 6.437

6.  Peer review of statistics in medical research. Reporting power calculations is important.

Authors:  Douglas G Altman; David Moher; Kenneth F Schulz
Journal:  BMJ       Date:  2002-08-31

7.  Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials.

Authors:  A S Detsky
Journal:  Stat Med       Date:  1990 Jan-Feb       Impact factor: 2.373

8.  Confidence intervals rather than P values: estimation rather than hypothesis testing.

Authors:  M J Gardner; D G Altman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-15

9.  The continuing unethical conduct of underpowered clinical trials.

Authors:  Scott D Halpern; Jason H T Karlawish; Jesse A Berlin
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

Review 10.  Reporting of sample size calculation in randomised controlled trials: review.

Authors:  Pierre Charles; Bruno Giraudeau; Agnes Dechartres; Gabriel Baron; Philippe Ravaud
Journal:  BMJ       Date:  2009-05-12
View more
  47 in total

1.  Small sample size is not the real problem.

Authors:  Peter Bacchetti
Journal:  Nat Rev Neurosci       Date:  2013-07-03       Impact factor: 34.870

2.  Emotion recognition and its relation to prefrontal function and network in heroin plus nicotine dependence: a pilot study.

Authors:  Hada Fong-Ha Ieong; Zhen Yuan
Journal:  Neurophotonics       Date:  2018-06-09       Impact factor: 3.593

3.  Pharmacy school survey standards revisited.

Authors:  Károly Mészáros; Mitchell J Barnett; Russell V Lenth; Katherine K Knapp
Journal:  Am J Pharm Educ       Date:  2013-02-12       Impact factor: 2.047

4.  Breaking free of sample size dogma to perform innovative translational research.

Authors:  Peter Bacchetti; Steven G Deeks; Joseph M McCune
Journal:  Sci Transl Med       Date:  2011-06-15       Impact factor: 17.956

Review 5.  Recommendations for planning pilot studies in clinical and translational research.

Authors:  Charity G Moore; Rickey E Carter; Paul J Nietert; Paul W Stewart
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

6.  The null hypothesis significance test in health sciences research (1995-2006): statistical analysis and interpretation.

Authors:  Luis Carlos Silva-Ayçaguer; Patricio Suárez-Gil; Ana Fernández-Somoano
Journal:  BMC Med Res Methodol       Date:  2010-05-19       Impact factor: 4.615

7.  Understanding the relevance of sample size calculation.

Authors:  Barun Kumar Nayak
Journal:  Indian J Ophthalmol       Date:  2010 Nov-Dec       Impact factor: 1.848

8.  Impact of Roux-en-Y gastric bypass on metabolic syndrome and insulin resistance parameters.

Authors:  Everton Cazzo; Martinho Antonio Gestic; Murillo Pimentel Utrini; Ricardo Rossetto Machado; Bruno Geloneze; José Carlos Pareja; Elinton Adami Chaim
Journal:  Diabetes Technol Ther       Date:  2013-12-03       Impact factor: 6.118

9.  Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit.

Authors:  Marie-Cécile Le Deley; Karla V Ballman; Julien Marandet; Daniel Sargent
Journal:  Clin Trials       Date:  2012-05-08       Impact factor: 2.486

10.  Protease activated-receptor 2 is necessary for neutrophil chemorepulsion induced by trypsin, tryptase, or dipeptidyl peptidase IV.

Authors:  Michael J V White; Luis E Chinea; Darrell Pilling; Richard H Gomer
Journal:  J Leukoc Biol       Date:  2017-12-11       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.